Benefits and risks of combination therapy for hepatitis B
Norah A. Terrault – 27 April 2009 – In successful antiviral therapy of hepatitis B, drug combinations, particularly combinations without cross‐resistance, can delay or prevent the emergence of drug‐resistant mutants. Because drug‐resistant mutants are archived and may limit future therapeutic options, prevention is important for long‐term therapeutic efficacy. Additionally, combining drugs may achieve synergistic or additive antiviral effects compared with single drug therapy.